2021年07月18日讯 /生物谷BIOON/ --美国食品和药物管理局（FDA）近日批准安斯泰来Prograf（中文商品名：普乐可复，通用名 ...

The FDA has approved Prograf (tacrolimus, from Astellas) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. This approval was based ...

Tacrolimus (Prograf ®, FK506, Fujisawa Healthcare) is a widely used immunosuppressive agent that is used both for the prevention and treatment of solid organ transplant rejection as well as for the ...

To develop a population pharmacokinetic (PopPK) model of tacrolimus in healthy Chinese volunteers and liver transplant recipients for investigating the difference between the populations, and for ...

A new granule formulation of Prograf (tacrolimus; Astellas) has been made available for the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplant, and ...

It's a pitched battle over Prograf. Fast-moving, too: FDA rejected Astellas Pharma's petition for tougher-than-normal approval standards for copycat forms of its transplant drug. Novartis got the FDA ...